Evidence map›Paper›PMID 42368154›Full record

ArticleACS omega2026

Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry.

Jiaojiao Sha, Zijin Geng, Shanyu Qi, Liangjia Du, Qianqian Hu, Minqi Cai, Dezhu Chen, Yiqiang Chen, Siyuan Liu, Hongyan Song and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiaojiao ShaDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China.
Zijin GengDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China.
Shanyu QiDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, China.
Liangjia DuDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Normal University, Nanjing, Jiangsu 210008, China.
Qianqian HuDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Normal University, Nanjing, Jiangsu 210008, China.
Minqi CaiDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.
Dezhu ChenDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.
Yiqiang ChenCenter for Precision Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.
Siyuan LiuCenter for Precision Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.
Hongyan SongDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.
Tianze LingSchool of Life Sciences, Tsinghua University, Beijing 100084, China.ORCID https://orcid.org/0009-0006-6715-2553
Cheng ChangState Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics-driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing 102206, China.ORCID https://orcid.org/0000-0002-0361-2438
Bing BaiDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China.ORCID https://orcid.org/0009-0002-1505-2965

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lecanemab is a humanized mouse monoclonal antibody that is clinically approved for treating Alzheimer's disease by binding to amyloid oligomers, protofibrils, and insoluble fibrils to clear Aβ aggregates in the brain. Although therapeutically effective, lecanemab is also associated with side effects, and its quality might vary among different batches due to impurities and modifications. Herein, we provide proteomics, intact protein, and

Identifiers

PMID42368154
PMCPMC13294873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.